Your browser is no longer supported. Please, upgrade your browser.
Settings
MTNB Matinas BioPharma Holdings, Inc. daily Stock Chart
MTNB [NYSE]
Matinas BioPharma Holdings, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own4.80% Shs Outstand98.61M Perf Week-2.76%
Market Cap35.50M Forward P/E- EPS next Y-0.14 Insider Trans- Shs Float72.45M Perf Month-15.45%
Income-15.50M PEG- EPS next Q-0.04 Inst Own8.30% Short Float2.22% Perf Quarter-40.38%
Sales0.20M P/S177.50 EPS this Y-74.50% Inst Trans-26.24% Short Ratio4.11 Perf Half Y-65.71%
Book/sh0.00 P/B- EPS next Y6.70% ROA-105.80% Target Price2.00 Perf Year-72.73%
Cash/sh0.09 P/C3.99 EPS next 5Y- ROE-677.90% 52W Range0.32 - 1.60 Perf YTD-68.97%
Dividend- P/FCF- EPS past 5Y- ROI3877.10% 52W High-75.63% Beta0.49
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low20.48% ATR0.03
Employees15 Current Ratio6.30 Sales Q/Q100.00% Oper. Margin- RSI (14)50.59 Volatility8.38% 9.31%
OptionableNo Debt/Eq- EPS Q/Q12.10% Profit Margin- Rel Volume0.13 Prev Close0.36
ShortableYes LT Debt/Eq- EarningsAug 21 BMO Payout- Avg Volume391.60K Price0.39
Recom2.00 SMA205.63% SMA50-7.62% SMA200-53.56% Volume22,015 Change8.33%
Aug-16-18 08:00AM  Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop GlobeNewswire
Aug-10-18 08:15AM  Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-09-18 09:15AM  NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology GlobeNewswire +12.05%
Jun-22-18 08:30AM  Matinas BioPharma Announces Closing of $8.0 Million Public Offering GlobeNewswire -5.27%
Jun-19-18 08:00AM  Matinas BioPharma Announces Pricing of $8.0 Million Public Offering GlobeNewswire -9.14%
Jun-12-18 08:00AM  Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host GlobeNewswire
Jun-06-18 12:26PM  Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near? Simply Wall St. +9.93%
07:35AM  Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform GlobeNewswire
May-10-18 07:05AM  Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-07-18 08:05AM  Matinas BioPharma to Host Quarterly Update Conference Call GlobeNewswire
May-01-18 08:05AM  Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference GlobeNewswire +35.33%
Apr-19-18 08:05AM  Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease GlobeNewswire
Mar-26-18 04:45PM  Matinas BioPharma Reports 2017 Financial Results GlobeNewswire
Mar-19-18 06:30AM  Matinas BioPharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-16-18 05:00PM  Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update GlobeNewswire
Mar-15-18 08:00AM  Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-12-18 08:05AM  Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast GlobeNewswire
Jan-08-18 07:01AM  Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis GlobeNewswire +9.09%
Dec-14-17 07:01AM  Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors GlobeNewswire
Nov-15-17 07:35AM  Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-11-17 08:05AM  Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference GlobeNewswire
Sep-19-17 09:20AM  Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 07:30AM  Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 GlobeNewswire
Aug-08-17 06:05AM  Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 GlobeNewswire +14.40%
05:50AM  Investor Network: Matinas BioPharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:05AM  Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire +6.67%
Aug-01-17 08:30AM  Matinas BioPharma to Host Quarterly Update Conference Call GlobeNewswire
Jun-26-17 01:15PM  Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today Motley Fool -27.80%
06:05AM  Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis GlobeNewswire
Jun-03-17 04:00PM  Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis GlobeNewswire
Jun-02-17 04:01PM  Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis GlobeNewswire
Jun-01-17 07:05AM  Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
May-30-17 08:05AM  Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiologys ASM Microbe 2017 Conference GlobeNewswire -11.33%
May-16-17 07:05AM  Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update GlobeNewswire
Apr-24-17 07:00AM  Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases GlobeNewswire
Apr-18-17 07:01AM  Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance GlobeNewswire
Apr-11-17 08:30AM  MonoSol Rx Appoints James S. Scibetta to Board of Directors GlobeNewswire
Apr-03-17 07:36PM  Edited Transcript of MTNB earnings conference call or presentation 3-Apr-17 12:30pm GMT Thomson Reuters StreetEvents +5.42%
07:06AM  Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update GlobeNewswire
Mar-30-17 07:05AM  Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors GlobeNewswire -7.09%
Mar-29-17 07:05AM  Matinas BioPharma to Host Fiscal Year 2016 Update Conference Call GlobeNewswire
Mar-28-17 07:35AM  Matinas BioPharma to Ring NYSE Closing Bell on March 29th, 2017 GlobeNewswire +15.69%
Mar-27-17 07:35AM  Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501 GlobeNewswire
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.